Mr. Chairman, Ms. Chairwoman, and Members of the Senate Drug Caucus, thank you for inviting the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to participate in this hearing to share what we know about the biology and the potential therapeutic effects of cannabidiol (CBD), one of the main active chemical compounds found in marijuana. In light of the rapidly evolving interest in the potential use of marijuana and its derivative compounds for medical purposes, it is important to take stock of what we know and do not know about the therapeutic potential of CBD.
One thing to keep in mind, however, is that in the United States, sometimes olive oil that’s labeled “extra virgin” is not what it claims to be. In 2015, the National Consumers League tested 11 different olive oils and found that six of them failed to meet the standards that classify them as extra virgin. Here’s a list of extra virgin olive oils that did pass the test; they include widely available brands like California Olive Ranch, Colavita and Lucini.
About 40 percent of the 84 items were "under-labeled," meaning they had significantly more CBD than indicated. In addition, approximately a quarter were "over-labeled," meaning consumers not only are paying good money for an ingredient they are not getting but also may not be getting a large enough dose to achieve any potential therapeutic benefit. More concerning, Bonn-Miller says, is that some CBD products may contain THC in amounts that could make you intoxicated or impaired
The reason so many people are interested in cannabis products that don’t make them high, proponents say, is that CBD helps with everything from pain and nausea to rheumatoid arthritis, cancer, Crohn’s disease, and dementia. CBD is anti-inflammatory, anti-anxiety, antibacterial, immunosuppressive, and more, says Joseph Cohen, D.O., a cannabis doctor in Boulder, CO.
THC’s intoxicating powers come from its ability to mimic anandamide, an endocannabinoid or naturally occurring mood-altering substance in the body that binds to CB1 receptors in the brain and is associated with having a rosy disposition. THC binds to anandamide’s CB1 receptors even more tightly than anandamide itself, triggering an exaggerated or euphoric response — in other words, you get high.
Locsta....I share your pain of degenerative and bulging disk disease, along with fibromyalgia, chronic fatigue and arthritis. Absolutely no energy and chronic pain all day, every day. I'm curious as to what type and brand of the CBD oil you are taking and for how long have you been using it? I've been researching CBD oil for months and am quite confused!
A: Mamun, Our Full spectrum CBD oil is great for assisting with pain, inflammation, sleep, anxiety and stress. Depending on the severity of the pain you are experiencing you will want to choose an oil that is stronger or weaker. 5x strength is the strongest option we have available. https://zatural.com/products/cannabis-sativa-hemp-oil-drops?variant=14337796210730
About 49% of the weight of hempseed is an edible oil that contains 76% as essential fatty acids; i.e., omega-6 fatty acids including linoleic acid (LA, 54%) and gamma-linolenic acid (GLA, 3%), omega-3 alpha-linolenic acid (ALA, 17%) in addition to monounsaturated fat (5% to 11%) and stearidonic acid (2%). Hemp seed oil contains 5% to 7% saturated fat. In common with other oils, hempseed oil provides 9 kcal/g. Compared with other culinary oils it is low in saturated fatty acids.
I have sporadic back spasms for year I see a chiropractor monthly for maintenance (it help) and deal with daily Knee & hip joint pain due to my job (heavy mechanic/steel work with lots of walking). after reading all the great reviews on CBD oil I want to get off the daily ibuprofen regiment and try CBD oil. I would like to try it as a gel cap but would like some advise on dosage size. I also want to know how often I should take the CBD treatments. any and all advise is appreciated
Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication.